Original language | English (US) |
---|---|
Pages (from-to) | 705-753 |
Number of pages | 49 |
Journal | The Lancet |
Volume | 397 |
Issue number | 10275 |
DOIs | |
State | Published - Feb 20 2021 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet, Vol. 397, No. 10275, 20.02.2021, p. 705-753.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Public policy and health in the Trump era
AU - Woolhandler, Steffie
AU - Himmelstein, David U.
AU - Ahmed, Sameer
AU - Bailey, Zinzi
AU - Bassett, Mary T.
AU - Bird, Michael
AU - Bor, Jacob
AU - Bor, David
AU - Carrasquillo, Olveen
AU - Chowkwanyun, Merlin
AU - Dickman, Samuel L.
AU - Fisher, Samantha
AU - Gaffney, Adam
AU - Galea, Sandro
AU - Gottfried, Richard N.
AU - Grumbach, Kevin
AU - Guyatt, Gordon
AU - Hansen, Helena
AU - Landrigan, Philip J.
AU - Lighty, Michael
AU - McKee, Martin
AU - McCormick, Danny
AU - McGregor, Alecia
AU - Mirza, Reza
AU - Morris, Juliana E.
AU - Mukherjee, Joia S.
AU - Nestle, Marion
AU - Prine, Linda
AU - Saadi, Altaf
AU - Schiff, Davida
AU - Shapiro, Martin
AU - Tesema, Lello
AU - Venkataramani, Atheendar
N1 - Funding Information: KG is a member of the Board of Canopy Health, a limited Knox-Keene licensed health plan in California, serving as one of 3 University of California San Francisco board members for this health plan for which UCSF is a principal equity shareholder. KG is also a member of Physicians for a National Health Program, an organisation advocating for a single payer health plan in the USA. AG is a leader of Physicians for a National Health Program, a non-profit organisation that favours expanding insurance through a single payer programme, AG is not paid by this organisation but some travel has been reimbursed. AV reports grants from Robert Wood Johnson Foundation, grants from National Institutes of Health, grants from Center for Financial Security (University of Wisconsin), grants from Commonwealth of Kentucky, outside the submitted work. All other authors declare no competing interests. Funding Information: Trump's pro-corporate agenda was epitomised by his appointment of Alex Azar (a former Eli Lilly executive) to head the US Department of Health and Human Services, a signal to the pharmaceutical and other industries that their price gouging and anti-competitive behaviours would escape regulation. As discussed, President Trump's well-publicised promises to reduce drug prices yielded no results. Instead, he supported large corporations. For example, in 2018, the administration threatened sanctions against Ecuador for promoting breastfeeding, which might cut into the market of US manufacturers of infant formula. 334 Azar celebrated Gilead's donation of 2·4 million bottles of emtricitabine and tenofovir (Truvada) to prevent HIV transmission in 200 000 patients, which was met by scorn from activists who labelled Gilead's actions a publicity stunt aimed at slowing the market entry of a generic competitor and promoting the firm's new drug. 335 After preliminary data showed that remdesivir shortened COVID-19 hospitalisations, Trump made a deal with Gilead to secure 90% of the world's supply of the drug for the USA in August and September, 2020. The deal will pay Gilead approximately US$3100 per 5-day course of treatment, for a drug that costs approximately US$10 to manufacture and the development of which was partly funded by government grants. 336 Similarly, the US Government has given US$10 billion to firms (eg, Moderna, Sanofi, GlaxoSmithKline) developing COVID-19 vaccines, without placing restrictions on the prices they can charge. Funding Information: The Commission was supported by grants from the Doris Duke Charitable Foundation and the Open Society Foundations, which covered costs of some members' travel and lodging for Commission meetings, and some data purchases. Commissioners were not compensated for their participation. Additional support came from in-kind contributions by the Boston University School of Public Health and the Roosevelt House Public Policy Institute at Hunter College of the City University of New York, which hosted Commission meetings. Some staff members of the Open Society Foundations attended some in-person Commission meetings as observers but played no role in drafting the report or recommendations. Jaime R Torres and Antonio I Fernandez (both from Latinos for Healthcare Equity) provided general advice and data for the Puerto Rico panel. Prof Alfredo Morabia (Barry Commoner Center for Health and the Environment, Queens College City, University of New York, NY, USA) was the senior adviser to the Commission. Mark Almberg (an independent consultant) served as the Commission's fact checker and editorial adviser.
PY - 2021/2/20
Y1 - 2021/2/20
UR - http://www.scopus.com/inward/record.url?scp=85100872258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100872258&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(20)32545-9
DO - 10.1016/S0140-6736(20)32545-9
M3 - Review article
C2 - 33581802
AN - SCOPUS:85100872258
SN - 0140-6736
VL - 397
SP - 705
EP - 753
JO - The Lancet
JF - The Lancet
IS - 10275
ER -